Suppr超能文献

血友病患儿初级预防的障碍:静脉通路问题。

Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

作者信息

Santagostino Elena, Mancuso Maria Elisa

机构信息

Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milano, Italia.

出版信息

Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s12-6. doi: 10.2450/2008.0031-08.

Abstract

Modem treatment for hemophilic children is based on prophylaxis and immune tolerance induction (ITI). Both treatment regimens are based on frequent infusions at early ages, therefore an adequate venous access is essential. Peripheral veins represent the best option, however, different solutions, as central venous access devices (CVADs) and arteriovenous fistulae (AVFs), can be adopted if needed. CVADs have been used in hemophiliacs, however their survival is affected by infectious complications. Among CVADs, fully implantable devices are usually preferred to external lines due to a lower infectious risk. The limited survival of CVADs may have a relevant impact on treatment outcome, especially in case of ITI where treatment interruptions are counterproductive. To overcome such drawbacks, internal AVF has been considered as an alternative option owing to a lower rate of infectious complications. Moreover, AVF is easy to use in the home setting and well accepted by children. Possible complications not preventing AVF use are postoperative hematoma and transient symptoms of distal ischemia; one case of symptomatic thrombosis has been reported so far. Long-term complications include loss of patency, aneurysmatic dilatation and, rarely, limb dysmetria and a regular follow-up is mandatory to allow early remedial intervention. Surgical dismantlement of AVF is recommended as soon as transition to peripheral veins is possible.

摘要

现代针对血友病患儿的治疗基于预防和免疫耐受诱导(ITI)。这两种治疗方案都基于在患儿早期进行频繁输注,因此充足的静脉通路至关重要。外周静脉是最佳选择,然而,如有需要,也可采用不同的解决方案,如中心静脉通路装置(CVADs)和动静脉内瘘(AVFs)。CVADs已用于血友病患者,但其使用寿命会受到感染并发症的影响。在CVADs中,由于感染风险较低,完全植入式装置通常比外部导管更受青睐。CVADs有限的使用寿命可能会对治疗结果产生重大影响,尤其是在ITI治疗中,治疗中断会产生适得其反的效果。为克服这些缺点,由于感染并发症发生率较低,内部AVF已被视为一种替代选择。此外,AVF在家中易于使用且深受患儿接受。不影响AVF使用的可能并发症包括术后血肿和远端缺血的短暂症状;迄今为止,已报告1例有症状的血栓形成。长期并发症包括通畅性丧失、动脉瘤样扩张,很少见的是肢体运动失调,必须进行定期随访以便早期进行补救干预。一旦有可能过渡到外周静脉,建议尽早手术拆除AVF。

相似文献

1
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.
Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s12-6. doi: 10.2450/2008.0031-08.
2
Arteriovenous fistula as stable venous access in children with severe haemophilia.
Haemophilia. 2010 Jan;16 Suppl 1:25-8. doi: 10.1111/j.1365-2516.2009.02158.x.
3
Venous access in haemophilic children: choice and management.
Haemophilia. 2010 Jan;16 Suppl 1:20-4. doi: 10.1111/j.1365-2516.2009.02156.x.
4
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Br J Haematol. 2008 May;141(5):689-95. doi: 10.1111/j.1365-2141.2008.07087.x. Epub 2008 Apr 10.
6
Complications of central venous access devices in paediatric haemophilia patients.
Haemophilia. 2003 Jan;9(1):50-6. doi: 10.1046/j.1365-2516.2003.00692.x.
7
Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Haemophilia. 2009 Jan;15(1):168-74. doi: 10.1111/j.1365-2516.2008.01906.x.
8
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up.
Haematologica. 2009 May;94(5):687-92. doi: 10.3324/haematol.2008.001594. Epub 2009 Mar 13.
9
Central venous access catheters in children with haemophilia.
Blood Coagul Fibrinolysis. 1996 Mar;7 Suppl 1:S39-44.
10
Implantable venous access devices in children with hemophilia: a report of low infection rates.
J Pediatr. 1998 Jun;132(6):934-8. doi: 10.1016/s0022-3476(98)70386-5.

引用本文的文献

2
Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Res Pract Thromb Haemost. 2020 Jul 29;4(7):1101-1113. doi: 10.1002/rth2.12412. eCollection 2020 Oct.
3
Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells.
Mol Ther. 2016 Mar;24(3):607-19. doi: 10.1038/mt.2015.223. Epub 2015 Dec 22.

本文引用的文献

1
Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience.
Haemophilia. 1997 Jul;3(3):194-8. doi: 10.1046/j.1365-2516.1997.00117.x.
3
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Br J Haematol. 2008 May;141(5):689-95. doi: 10.1111/j.1365-2141.2008.07087.x. Epub 2008 Apr 10.
4
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
N Engl J Med. 2007 Aug 9;357(6):535-44. doi: 10.1056/NEJMoa067659.
5
International workshop on immune tolerance induction: consensus recommendations.
Haemophilia. 2007 Jul;13 Suppl 1:1-22. doi: 10.1111/j.1365-2516.2007.01497.x.
6
Arteriovenous fistula for long-term venous access for boys with hemophilia.
J Vasc Surg. 2007 May;45(5):986-90; discussion 990-1. doi: 10.1016/j.jvs.2006.12.060. Epub 2007 Mar 21.
7
The international immune tolerance study: a multicenter prospective randomized trial in progress.
J Thromb Haemost. 2006 Oct;4(10):2271-3. doi: 10.1111/j.1538-7836.2006.02127.x. Epub 2006 Jul 17.
9
A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia.
J Thromb Haemost. 2004 May;2(5):737-42. doi: 10.1111/j.1538-7836.2004.00653.x.
10
Central venous access devices in haemophilia.
Haemophilia. 2004 Mar;10(2):134-46. doi: 10.1046/j.1365-2516.2003.00840.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验